Cognition Therapeutics, Inc. (CGTX)
NASDAQ: CGTX · Real-Time Price · USD
1.120
+0.080 (7.69%)
At close: Feb 25, 2026, 4:00 PM EST
1.150
+0.030 (2.68%)
Pre-market: Feb 26, 2026, 5:53 AM EST
Cognition Therapeutics Employees
As of December 31, 2024, Cognition Therapeutics had 28 total employees, including 25 full-time and 3 part-time employees. The number of employees did not change compared to the previous year.
Employees
28
Change (1Y)
n/a
Growth (1Y)
n/a
Revenue / Employee
n/a
Profits / Employee
-$999,500
Market Cap
98.87M
Employees Chart
Employees History
| Date | Employees | Change (1Y) | Growth (1Y) | Full-Time | Part-Time |
|---|---|---|---|---|---|
| Dec 31, 2024 | 28 | 0 | - | 25 | 3 |
| Dec 31, 2023 | 28 | 3 | 12.00% | 25 | 3 |
| Dec 31, 2022 | 25 | 4 | 19.05% | 22 | 3 |
| Dec 31, 2021 | 21 | 1 | 5.00% | 19 | 2 |
| Sep 30, 2021 | 18 | -2 | -10.00% | 15 | 3 |
| Jun 30, 2021 | 22 | - | - | 18 | 4 |
| Mar 31, 2021 | 22 | - | - | 20 | 2 |
| Dec 31, 2020 | 20 | - | - | 18 | 2 |
Related Stocks
| Company Name | Employees |
|---|---|
| Gossamer Bio | 145 |
| Verrica Pharmaceuticals | 71 |
| Precision BioSciences | 67 |
| aTyr Pharma | 65 |
| Pyxis Oncology | 44 |
| Biomea Fusion | 42 |
| MAIA Biotechnology | 13 |
| Dogwood Therapeutics | 12 |
CGTX News
- 20 days ago - Cognition Therapeutics Extends Expanded Access Program for Zervimesine (CT1812) in Dementia with Lewy Bodies - GlobeNewsWire
- 4 weeks ago - Cognition Therapeutics Completes Type C Meeting with FDA for Zervimesine (CT1812) in Dementia with Lewy Bodies - GlobeNewsWire
- 7 weeks ago - Cognition Therapeutics Publishes Phase 2 Clinical Results Showing Zervimesine's Potential to Slow the Progression of Dementia with Lewy Bodies - GlobeNewsWire
- 3 months ago - Cognition Therapeutics Presents Phase 3 Plan for Zervimesine (CT1812) in Alzheimer's Disease at Clinical Trials on Alzheimer's Disease (CTAD) Conference - GlobeNewsWire
- 3 months ago - Cognition Therapeutics to Participate in 37th Annual Piper Sandler Healthcare Conference - GlobeNewsWire
- 3 months ago - Cognition Therapeutics Completes Enrollment in Phase 2 Study of Zervimesine (CT1812) in Early Alzheimer's Disease - GlobeNewsWire
- 3 months ago - Cognition Therapeutics Reports Financial Results for the Third Quarter 2025 and Highlights Progress Across Clinical Programs - GlobeNewsWire
- 6 months ago - Cognition Therapeutics Study of Zervimesine (CT1812) in Early Alzheimer's Disease Reaches 75% Enrollment Target - GlobeNewsWire